Urothelial Cancer Clinical Trials

Find Urothelial Cancer Clinical Trials Near You

Evaluation of the Efficacy of Bladder EpiCheck® for the Primary Detection of Urothelial Carcinoma in Subjects Presenting With Haematuria

Status: Recruiting
Location: See all (5) locations...
Intervention Type: Diagnostic test
Study Type: Observational
SUMMARY

The goal of this observational study is to further validate the sensitivity and specificity of Bladder EpiCheck in primary detection of urothelial carcinoma in participants aged 45 years or older presenting with haematuria, compared to cystoscopy and pathology, if performed. Participants will provide a voided urine sample, and data from standard of care haematuria work-up will be collected.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 45
Healthy Volunteers: f
View:

• Participants aged 45 years or older

• Participants who are willing and able to provide written informed consent and adhere to study procedures

• Participants presenting with visible and/or non-visible haematuria within 6 months prior to study enrollment

• Participants scheduled to undergo standard of care cystoscopy for urinary bladder examination within 60 days after study enrollment

• Participants who are able to produce at least 10 ml of voided urine

Locations
Other Locations
United Kingdom
Addenbrooke's Hospital
RECRUITING
Cambridge
NHS Fife
RECRUITING
Dunfermline
NHS Lothian
RECRUITING
Edinburgh
Guy's and St Thomas
RECRUITING
London
Frimley
RECRUITING
Surrey Quays
Contact Information
Primary
Vered Yayon
vered.y@nucleix.com
+972-8-9161616
Backup
Admin.
info@nucleix.com
Time Frame
Start Date: 2025-06-20
Estimated Completion Date: 2026-12
Participants
Target number of participants: 800
Treatments
aged ≥ 45 years with haematuria scheduled for cystoscopy, for suspicion of urothelial carcinoma
Adult participants aged ≥ 45 years presenting with haematuria in the past 6 months, scheduled to undergo haematuria workup, including cystoscopy, for suspicion of urothelial carcinoma.
Related Therapeutic Areas
Sponsors
Leads: Nucleix Ltd.

This content was sourced from clinicaltrials.gov

Similar Clinical Trials